Investigating how MALT1 protease affects tumor growth and immune response in a type of brain cancer.
MALT1 protease as a regulator of anti-tumor immunity and tumor progression in diffuse midline glioma
This study is looking at a tough brain tumor in kids called H3K27M-mutant diffuse midline glioma, and it’s testing whether blocking a protein called MALT1 can help improve treatment and boost the body’s ability to fight the cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10884215 on NIH RePORTER |
What this research studies
This research focuses on H3K27M-mutant diffuse midline glioma, a challenging pediatric brain tumor that is difficult to treat. The study aims to explore the role of MALT1 protease, a protein that influences cancer cell survival and immune responses, in the progression of this tumor. By inhibiting MALT1, the researchers hope to find a way to improve treatment outcomes and enhance anti-tumor immunity. This approach could lead to safer and more effective therapies for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with H3K27M-mutant diffuse midline glioma.
Not a fit: Patients with other types of brain tumors or those without the H3K27M mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates and quality of life for children with this aggressive brain tumor.
How similar studies have performed: While the approach of targeting MALT1 in gliomas is relatively novel, preliminary studies suggest that similar strategies have shown promise in other cancer types.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Butterfield, Hannah — University of Pittsburgh at Pittsburgh
- Study coordinator: Butterfield, Hannah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.